1.21

2.42% -0.03

Century Therapeutics Inc (IPSC)

Overview News Price History Option Chain Financials Discussions Forecast

Century Therapeutics Inc stock is traded at $1.21, with a volume of 516.15K. It is down -2.42% in the last 24 hours and down -23.42% over the past month. Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

Previous Close:

$1.24

Open:

$1.22

24h Volume:

516.15K

Relative Volume:

1.35

Market Cap:

$104.16M

Revenue:

$2.24M

Net Income/Loss:

$-136.67M

P/E Ratio:

-0.5576

EPS:

-2.17

Net Cash Flow:

$-102.08M

1W Performance:

-0.82%

1M Performance:

-23.42%

6M Performance:

-63.33%

1Y Performance:

-21.94%

1-Day Range:

$1.20

$1.27

1-Week Range:

$1.20

$1.2901

52-Week Range:

$1.14

$5.51

Century Therapeutics Inc Stock (IPSC) Company Profile

Name

Century Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

215-981-4000

Address

25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA

Employee

165

Twitter

Next Earnings Date

Latest SEC Filings

IPSC's Discussions on Twitter

Compare IPSC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IPSC	1.21	104.16M	2.24M	-136.67M	-102.08M	-2.17
VRTX	450.97	116.38B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	82.09B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.14B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.25B	3.30B	-501.07M	1.03B	11.54

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-27-22	Initiated	Chardan Capital Markets	Buy
Oct-31-22	Initiated	Guggenheim	Buy
Oct-10-22	Initiated	Canaccord Genuity	Buy
May-23-22	Initiated	H.C. Wainwright	Buy
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	BofA Securities	Buy
Jul-13-21	Initiated	JP Morgan	Overweight
Jul-13-21	Initiated	Piper Sandler	Overweight

View All

Century Therapeutics Inc Stock (IPSC) Latest News

Nov 20, 2024

Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MSN

Nov 20, 2024

Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - The Malaysian Reserve

Nov 20, 2024

Nov 19, 2024

Endo, Inc. Partners with MC2 Therapeutics to Bring Wynzora® Cream to Canadian Market - MyChesCo

Nov 19, 2024

Nov 18, 2024

Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace

Nov 18, 2024

Nov 14, 2024

Syncona Portfolio Ltd's Strategic Acquisition of Autolus Therape - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

FMR LLC's Strategic Reduction in Century Therapeutics Inc Holdin - GuruFocus.com

Nov 13, 2024

Nov 11, 2024

NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Nov 11, 2024

Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MyChesCo

Nov 11, 2024

Century Therapeutics to Present Cutting-Edge Preclinical Data at 2024 ASH Annual Meeting - MSN

Nov 11, 2024

Nov 10, 2024

Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MyChesCo

Nov 10, 2024

Nov 09, 2024

William Blair Has Positive Estimate for IPSC FY2024 Earnings - Defense World

Nov 09, 2024

Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo

Nov 09, 2024